Isotiorga (Isotretinoin)

Isotretinoin binds to retinoic acid receptors in skin cells, altering gene expression that controls keratinocyte differentiation and sebaceous gland activity. This reduces sebum production, shrinks gland size, and exerts anti‑inflammatory effects, thereby decreasing follicular blockage and bacterial growth that cause acne.

The dosage of Isotiorga is individualized by the prescribing clinician based on the patient’s weight, severity of acne, and laboratory parameters. The prescriber determines the appropriate daily amount and treatment duration, which is typically several months, and adjusts it according to response and safety monitoring.

Isotiorga is classified as pregnancy category X because isotretinoin is highly teratogenic and can cause severe birth defects. It must not be used by pregnant women or women who may become pregnant. Breastfeeding is also contraindicated, as isotretinoin is excreted in milk and may harm the infant.

To order Isotiorga, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Compared with oral antibiotics or hormonal therapy, isotretinoin offers a disease‑modifying effect that can produce long‑term remission after a finite course. Unlike topical retinoids, it works systemically to reduce sebum output. However, its safety profile requires more intensive monitoring, making it a second‑line option after other therapies have failed.

Isotiorga should be stored at temperatures below 25 °C, in its original container, protected from moisture and direct sunlight. Keep the product out of reach of children and do not store in bathrooms or near heat sources. No special refrigeration is needed for this oral formulation.

Isotiorga is taken orally, usually with a meal to improve absorption and reduce gastrointestinal irritation. The tablet or capsule is swallowed whole with water. Patients should follow the prescriber’s instructions regarding timing, food intake, and any required laboratory monitoring during therapy.

The most serious risks include teratogenicity, severe depression or suicidal ideation, inflammatory bowel disease, pancreatitis, and significant elevations in liver enzymes or triglycerides. Patients should be monitored closely for mood changes, abdominal pain, visual disturbances, and laboratory abnormalities throughout treatment.

Isotiorga is contraindicated in pregnant women, women planning pregnancy, and nursing mothers. It should also be avoided in patients with hypersensitivity to isotretinoin or any component of the formulation, those with uncontrolled hyperlipidaemia, severe liver disease, or a history of severe depression without appropriate psychiatric supervision.